A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


November 9, 2011

PSI-7977, Peg-Interferon, Ribavirin Combo Shines in Genotype 1 Hep C Study

Combining Pharmasset’s once-daily experimental nucleotide analog PSI-7977 with pegylated interferon and ribavirin cured 91 percent of 47 people with hepatitis C genotype 1 after 24 weeks of treatment. These exciting results from PROTON, a Phase II clinical trial, were reported on Tuesday, November 8, at the 62nd annual meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.

Genotype 1 is the most common type of hepatitis C virus (HCV) in the United States, and it’s harder to treat than other genotypes. After 48 weeks of pegylated interferon and ribavirin, about 50 percent of people with HCV genotype 1 are cured. Adding Incivek or Victrelis, the two approved HCV protease inhibitors, increases the cure rate to about 70 percent and may shorten treatment for people with HCV genotype 1.

PROTON enrolled people with genotype 1 who had never received HCV treatment. Most of them had subtype 1a, which is harder to cure than subtype 1b. About one quarter of PROTON’s participants were black or Latino. People with cirrhosis were not included in PROTON.

Two PSI-7977 dosing groups were included in PROTON. One group took 200 milligrams (mg) of PSI-7977 once daily in combination with pegylated interferon and ribavirin for 12 weeks. The second group took 400 mg of PSI-7977 once daily together with pegylated interferon and ribavirin for 12 weeks. Both groups continued pegylated interferon/ribavirin, without PSI-7977, for an additional 12 weeks.

A control group was also included in the study. In this group, study volunteers received a total of 48 weeks of pegylated interferon plus ribavirin without PSI-7977.

Adding PSI-7977 to pegylated interferon and ribavirin significantly increased cure rates, noted study presenter Eric Lawitz, MD, from Alamo Medical Research in San Antonio, Texas, and his colleagues. Since the control group was treated for 48 weeks, only end-of-treatment (EOT) response rates were available. At EOT, 50 percent of 26 people in the control group had undetectable HCV viral loads. In contrast, 91 percent of people treated with 400 mg PSI-7977 plus pegylated interferon and ribavirin had undetectable viral loads 12 weeks after completing therapy—a sustained virologic response (SVR), or viral cure rate. 

In the lower-dose group, the SVR was 88 percent. Of the four people in this group who were not cured, one person relapsed after treatment, and three of them experienced viral load rebounds while they were taking pegylated interferon and ribavirin without PSI-7977.

There were no viral rebounds in the 400 mg group. The person who did not achieve SVR in the 400 mg group relapsed after finishing treatment. According to Lawitz, there was no evidence of drug resistance among the five people who were not cured.

Of note, PSI-7977 worked just as well for people with the IL-28B TT genotype, which is predictive of a poor response to pegylated interferon and ribavirin. Lawitz noted that people with the TT genotype who received PSI-7977 had an initial rapid response to treatment and maintained it; all 13 of them were cured. According to Lawitz, “The high SVR in HCV genotype 1 was independent of predictors of poor interferon response.”

PROTON’S dropout rates were very low; three people left because of side effects from pegylated interferon and ribavirin, and two people were lost to follow-up. Fatigue, headache and chills were more common among people in the placebo group. Overall, side effects were similar across the study arms except for insomnia, which was more common among people who were given the 400 mg dose of PSI-7977.

Although mild to moderate lab abnormalities were similar in all study groups, severe drops in all white blood cells and in neutrophils—a specific type of white blood cell—were reported in 2 percent to 4 percent of people taking PSI-7977 versus none of the study volunteers in the placebo group. Moderate-to-severe anemia developed among 31 percent of people given the 200 mg dose of PSI-7977 versus 17 percent of the 400 mg arm and 15 percent of the placebo group.

In summary, Lawitz noted that “PSI-7977 was very well-tolerated, with no attributable safety signal, and no discontinuations were related to PSI-7977.”

Results from ELECTRON, a Phase II study of PSI-7977 in people with HCV genotypes 2 and 3, are also promising: 12 weeks of PSI-7977 and ribavirin, without pegylated interferon, cured 100 percent of 10 people. The study has been amended to add people with HCV genotype 1. Both first-time treatment takers and previous null responders with HCV genotype 1 are being treated with 12 weeks of PSI-7977 and ribavirin in ELECTRON.

Pharmasset recently announced its Phase III clinical trial program. Two studies—FISSION and POSITRON—will further explore the safety and efficacy of PSI-7977 plus ribavirin, but without pegylated interferon, in approximately 725 people with genotype 2/3 HCV infection. A third study will explore PSI-7977 in HCV genotype 1 patients, with the design of the study determined by the amended ELECTRON clinical trial and another study still under way.

Search: PSI-7977, hepatitis C, HCV, genotype 1, G1, SVR, cure, AASLD, Lawitz

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.